Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1016/j.mehy.2020.109767 http://scihub22266oqcxt.onion/10.1016/j.mehy.2020.109767 32353742!7177149!32353742     free     free     free Deprecated: Implicit conversion from float 215.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 215.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Med+Hypotheses 2020 ; 140 (ä): 109767 Nephropedia Template TP {{tp|p=32353742|t=2020. Vitamin D: A simpler alternative to tocilizumab for trial in COVID-19?|pdf=|usr=}}{{32353742}} gab.com Text Vitamin D: A simpler alternative to tocilizumab for trial in COVID-19 JO: Med Hypotheses http://www.kidney.de/pget.php?&tw=1&pmid=32353742 #FOAvip There is anecdotal evidence that tocilizumab, an immunosuppressant drug, may be a potential therapeutic option for patients with severe manifestations of coronavirus disease 2019 (COVID-19). Like tocilizumab, Vitamin D appears to modulate the activity of an interleukin (IL-6), which may explain the seasonal variation in prevalence of influenza. While most cases of COVID-19 have, thus far, occurred in the Northern Hemisphere winter, limiting the ability to assess seasonal variation, there remains substantial variation in the severity of this condition that has yet to be explained. A retrospective comparison of Vitamin D levels in previously obtained blood samples between survivors and confirmed fatalities could establish a rationale for implementation of widespread Vitamin D supplementation. This would be far cheaper and simpler than tocilizumab as a therapeutic option to trial. Twit Text FOAVip Vitamin D: A simpler alternative to tocilizumab for trial in COVID-19 ????Med Hypotheses http://www.kidney.de/pget.php?&tw=1&pmid=32353742 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=32353742 #FOAvip English Wikipedia <ref>{{Cite pmid|32353742}}</ref> Vitamin D: A simpler alternative to tocilizumab for trial in COVID-19? #MMPMID32353742 Silberstein M Med Hypotheses 2020[Jul]; 140 (ä): 109767 PMID32353742show ga There is anecdotal evidence that tocilizumab, an immunosuppressant drug, may be a potential therapeutic option for patients with severe manifestations of coronavirus disease 2019 (COVID-19). Like tocilizumab, Vitamin D appears to modulate the activity of an interleukin (IL-6), which may explain the seasonal variation in prevalence of influenza. While most cases of COVID-19 have, thus far, occurred in the Northern Hemisphere winter, limiting the ability to assess seasonal variation, there remains substantial variation in the severity of this condition that has yet to be explained. A retrospective comparison of Vitamin D levels in previously obtained blood samples between survivors and confirmed fatalities could establish a rationale for implementation of widespread Vitamin D supplementation. This would be far cheaper and simpler than tocilizumab as a therapeutic option to trial. |Antibodies, Monoclonal, Humanized/*therapeutic use[MESH] |Betacoronavirus[MESH] |COVID-19[MESH] |COVID-19 Drug Treatment[MESH] |Clinical Trials as Topic[MESH] |Coronavirus Infections/*drug therapy[MESH] |Dietary Supplements[MESH] |Humans[MESH] |Immunosuppressive Agents/therapeutic use[MESH] |Interleukin-6/immunology[MESH] |Pandemics[MESH] |Pneumonia, Viral/*drug therapy[MESH] |Prevalence[MESH] |SARS-CoV-2[MESH] |Vitamin D Deficiency/complications[MESH]Vitamin D: A simpler alternative to tocilizumab for trial in COVID-19?(epmc).pdf DeepDyve Pubget Overpricing